Literature DB >> 24322198

Perioperative chemotherapy in locally advanced gastric cancer.

Thales Paulo Batista1, Candice Amorim de Araújo Lima Santos, Gustavo Fernandes Godoy Almeida.   

Abstract

Gastric cancer is one of the most common cancers and a main cause of cancer-related death worldwide, since the majority of patients suffering of this malignancy are usually faced with a poor prognosis due to diagnosis at later stages. In order to improve treatment outcomes, the association of surgery with chemo and/or radiotherapy (multimodal therapy) has become the standard treatment for locally advanced stages. However, despite several treatment options currently available for management of these tumors, perioperative chemotherapy has been mainly accepted for the comprehensive therapeutic strategy including an appropriated D2-gastrectomy. This manuscript presents a (nonsystematic) critical review about the use of perioperative chemotherapy, with a special focus on the drugs delivery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24322198     DOI: 10.1590/S0004-28032013000200042

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  6 in total

1.  Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer.

Authors:  Yu Cheng; Jin Zhou; Honglun Li
Journal:  Clin Transl Sci       Date:  2015-02-14       Impact factor: 4.689

Review 2.  Facing Cell Autophagy in Gastric Cancer - What Do We Know so Far?

Authors:  Ting Xiu; Qie Guo; Fan-Bo Jing
Journal:  Int J Gen Med       Date:  2021-05-03

3.  Decreased expression of eukaryotic initiation factor 3f is an adverse prognostic factor for stage I-III gastric cancer.

Authors:  Guanghua Li; Na Wang; Chuanjin Sun; Bo Li
Journal:  World J Surg Oncol       Date:  2014-03-28       Impact factor: 2.754

4.  ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells.

Authors:  Rui Xie; Jia Liu; Xuefeng Yu; Chunfeng Li; Yufeng Wang; Wei Yang; Jiahe Hu; Ping Liu; Hong Sui; Peiqiang Liang; Xinyan Huang; Lijuan Wang; Yuxian Bai; Yingwei Xue; Jiuxin Zhu; Tianyi Fang
Journal:  J Oncol       Date:  2019-05-02       Impact factor: 4.375

5.  Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL-17 via the Bax/Bcl-2 signaling pathway.

Authors:  Tianxi Wang; Jun Zhang; Lihong Cui
Journal:  Exp Ther Med       Date:  2021-04-19       Impact factor: 2.447

6.  Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis.

Authors:  Qie Guo; Fan-Jing Jing; Wen Xu; Xiao Li; Xin Li; Jia-Lin Sun; Xiao-Min Xing; Chang-Kai Zhou; Fan-Bo Jing
Journal:  Aging (Albany NY)       Date:  2019-12-31       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.